Form 4: Zenas BioPharma: Fairmount Funds Management Reports Conversion of Preferred Stock and Option Grant Following IPO

Fairmount Funds Management and related parties report the conversion of preferred stock to common stock and an option grant following Zenas BioPharma's initial public offering.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Harwin filed a Form 4 detailing changes in beneficial ownership of Zenas BioPharma, Inc. [ZBIO] securities.
• The filing reports the automatic conversion of Series Seed, A, B, and C Convertible Preferred Stock into common stock on September 16, 2024, upon the closing of Zenas BioPharma's IPO.
• The conversion ratio was 8.6831-for-1 for all series of preferred stock.
• Fairmount Healthcare Fund II L.P. acquired 300,000 shares of common stock at $17 per share on September 16, 2024.
• Tomas Kiselak received an option to buy 37,000 shares of common stock on September 12, 2024, at an exercise price of $0, vesting annually over three years starting September 12, 2025, and expiring on September 11, 2034.
• Fairmount Funds Management LLC, as the investment manager for Fairmount Healthcare Fund II L.P., disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest.
• Tomas Kiselak and Peter Harwin, as managing members of Fairmount Funds Management GP LLC, also disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects standard post-IPO transactions and reporting, indicating a neutral to slightly positive sentiment due to the increased liquidity and simplified capital structure.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Zenas BioPharma following its IPO.
• The purchase of 300,000 shares by Fairmount Healthcare Fund II L.P. at $17 per share indicates confidence in the company's prospects.
• The option grant to Tomas Kiselak incentivizes continued service and alignment with the company's success.

Risks

• The filing indicates potential indirect beneficial ownership by multiple parties, which could lead to complex ownership structures.
• Disclaimer of beneficial ownership by Fairmount and its managing members could indicate a desire to limit liability or responsibility.

Industry Context

Form 4 filings are standard practice following significant transactions such as IPOs, providing transparency into changes in ownership by insiders and significant shareholders. This filing indicates the expected conversion of preferred equity into common equity upon the company becoming public.

Comparison to Industry Standards

• The conversion of preferred stock to common stock upon an IPO is a common practice in the biotechnology industry, aligning the interests of early investors with public shareholders.
• The size of the stock option grant to Tomas Kiselak is within the typical range for directors and key personnel in similarly sized biotech companies.
• The reporting structure involving multiple entities (Fairmount Funds Management, Fairmount Healthcare Fund II L.P., and individual managing members) is common for investment firms managing funds with holdings in public companies.

Stakeholder Impact

• Shareholders: The conversion of preferred stock to common stock may dilute existing shareholders, but it also simplifies the capital structure.
• Employees: The option grant to Tomas Kiselak incentivizes continued service and alignment with the company's success.
• Investors: The filing provides transparency into the ownership structure of the company.

Key Dates